Clinical Trials Directory

Trials / Completed

CompletedNCT01299350

Nt-proBNP Versus Clinical Guided Discharge in Acute Heart Failure

Randomized Comparison Between Nt-proBNP or Clinical Guided Discharges in Patients Hospitalized With Acute Heart Failure

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
125 (actual)
Sponsor
University of Valencia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Our objective is to compare a policy of hospital discharge guided by NT-proBNP levels versus discharge guided by conventional clinical criteria, in patients admitted with acute heart failure. The hypothesis is that the Nt-proBNP guided discharge will shorten hospital stay without worsening the outcome

Detailed description

Nt-proBNP levels as well as their response to pharmacological treatment are predictive of prognosis in patients with heart failure. The purpose of the present project is to investigate, in patients hospitalized with acute heart failure, whether a discharge decision guided by Nt-proBNP response shortens hospital stay and improves prognosis The included patients will be randomly assigned to one of these two strategies: hospital discharge according to clinical conventional criteria or discharge guided by Nt-proBNP. All patients will be treated following clinical guidelines. In the guided Nt-proBNP strategy, patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. In the conventional strategy, patients will be discharged at criterion of the attending cardiologist according to clinical assessment without Nt-proBNP. The main outcome will be the number of days of hospitalization at the index episode, and the secondary outcome will be death or readmission by heart failure at one and 6 months. Our hypothesis is that the Nt-proBNP guided discharge will allow to precisely evaluate the response to treatment and to determine the best time for hospital discharge. This will reduce hospital stay and death or readmission rate after discharge.

Conditions

Interventions

TypeNameDescription
OTHERNt-proBNP guided dischargeEvery patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies

Timeline

Start date
2010-11-01
Primary completion
2012-10-01
Completion
2013-03-01
First posted
2011-02-18
Last updated
2014-04-10

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT01299350. Inclusion in this directory is not an endorsement.

Nt-proBNP Versus Clinical Guided Discharge in Acute Heart Failure (NCT01299350) · Clinical Trials Directory